Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

The addition of vorinostat to lenalidomide/dexamethasone represents a novel combination therapy in multiple myeloma (MM), informed by laboratory studies suggesting synergy. This was a phase I, multicenter, open-label, non-randomized, dose-escalating study in patients with relapsed or relapsed and re...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Siegel, D S, Richardson, P, Dimopoulos, M, Moreau, P, Mitsiades, C, Weber, D, Houp, J, Gause, C, Vuocolo, S, Eid, J, Graef, T, Anderson, K C
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2014
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3944659/
https://ncbi.nlm.nih.gov/pubmed/24562384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2014.1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares